Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
| ▸ | PYGB | P11216 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23848882 | 1.00 | GBA1 (0.46) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL8347365 | 1.00 | GBA1 (0.46) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL16644800 | 1.00 | GBA1 (0.46) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL16628196 | 1.00 | GBA1 (0.46) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL12993503 | 1.00 | GBA1 (0.46) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL9621629 | 0.98 | OGA (0.42) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL18051737 | 0.94 | GBA1 (0.46) | GBA1LGALS1LGALS3LGALS9LGALS8 | |
| SCHEMBL24257396 | 0.92 | GBA1 (0.49) | GBA1GAA | |
| SCHEMBL24641098 | 0.92 | GBA1 (0.49) | GBA1GAA | |
| SCHEMBL21391555 | 0.92 | GBA1 (0.49) | GBA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280836-A1 | Anti-hypercholesterolemic biaryl azetidinone compounds | MORRIELLO GREGORI J | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280836-A1 | Anti-hypercholesterolemic biaryl azetidinone compounds | APOB, PCSK9, CYP46A1 | GBA1 1456/4885LGALS1 3397/4885LGALS3 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.